The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules

BACKGROUND: Cysteamine bitartrate delayed-release (DR) capsule (Procysbi(®)) is approved for treatment of nephropathic cystinosis in the USA, Canada, and the EU. The capsules contain cysteamine bitartrate beads that are enteric coated with acid-resistant Eudragit L 30 D-55, preventing drug release i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavloff, Nadine, Hauser, Terry A, Williams, Chris, Isbell, Sara Louis, Cadieux, Ben, Johnson, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132578/
https://www.ncbi.nlm.nih.gov/pubmed/30233142
http://dx.doi.org/10.2147/DDDT.S174928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132578/
https://www.ncbi.nlm.nih.gov/pubmed/30233142
http://dx.doi.org/10.2147/DDDT.S174928

Ejemplares similares